Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adapalene is a third-generation topical retinoid used primarily for the treatment of mild to severe acne vulgaris in adolescents and adults. It is a synthetic naphthoic acid derivative with retinoid activity that acts as an agonist at nuclear retinoic acid receptor beta and retinoic acid receptor gamma, which then form complexes with retinoid X receptors (RXRs) to modulate gene transcription. This leads to normalization of keratinocyte differentiation and decreased microcomedone formation. Adapalene also exhibits anti-inflammatory effects by inhibiting lipoxygenase activity and the oxidative metabolism of arachidonic acid into prostaglandins, as well as downregulating toll-like receptor 2 (TLR-2) expression and inhibiting activator protein 1 (AP-1). Its chemical stability allows it to be used alongside benzoyl peroxide without significant degradation. Adapalene is approved for use in patients aged 12 years or older[1][2][3][5][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adapalene.